Liver Disease Clinical Trials

Showing 981-1000 of 1,498 trials

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

NCT04278820

TQA3526 is a modified bile acid and FXR agonist. FXR is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to help with digestion. It is hypothesized that regular treatment with TQA3526 will improve liver function in persons with Primary Biliary Cirrhosis (PBC).

Primary Biliary Cirrhosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.130 participantsStarted Mar 2020

Changchun, Jilin, China

UNKNOWNNA

Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis

NCT03123666

Informed consent obtained from the patient or the patient's legal surrogate. The window for randomization and initiation of study drug infusion is 2 days from day of Admission. All further time points are relative to the day of randomization. Patients will be randomized (1:1) to receive either recombinant human GM-CSF or placebo. Using randomized block design of 10 each generated by computer and provided in sequential, sealed, opaque envelopes. Subjects will be stratified based on Child status. Patients who fulfil the inclusion criteria will receive either slow IV infusion of GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer for 7 days OR Placebo(saline infusion and saline nebulization). Standard medical care will be given in both limbs.

Cirrhosis

Institute of Liver and Biliary Sciences, India160 participantsStarted Apr 2017

New Delhi, National Capital Territory of Delhi, India

UNKNOWNNA

Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis

NCT03069339

Study Design: Open labeled randomized controlled trial. The study will be conducted on patients attending outpatient or admitted to admitted to Department of Hepatology from January 2017 to December 2018 at ILBS, New Delhi

Cirrhosis

Institute of Liver and Biliary Sciences, India330 participantsStarted Mar 2017

New Delhi, National Capital Territory of Delhi, India

A Study of TQA3526 in the Treatment of Primary Biliary Cirrhosis (PBC)

Recombinant Human Granulocyte Monocyte - Colony Stimulating Factor (GM CSF) for Prevention of Pneumonia in Patients With Cirrhosis

Carvedilol, Endoscopic Variceal Ligation or Combination of Both for Prevention of First Variceal Bleed in Child's B & C Cirrhosis

Related Searches

RAI & HRS: Relationship Between Relative Adrenal Insufficiency and Failure of Treatment in Hepatorenal Syndrome

De Novo Lipogenesis, Lipid and Carbohydrate Metabolism in Non-alcoholic Fatty Liver Disease

Safety and Efficacy of Grazoprevir and Elbasvir for GT1ang GT6 With and Without HIV

ADAMTS-13 and Von Willebrand Factor Levels and Activities in Children With Cirrhosis and/or Portal Hypertension

TIPS vs. NSBB Plus Endotherapy for the Prevention of Variceal Rebleeding in NSBB Non-responders of Primary Prophylaxis

Tesamorelin Effects on Liver Fat and Histology in HIV

Evidence-based Laboratory Test Order Sets in Primary Care

Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis

Novel Molecular Spectrometric Biomarkers in Blood Plasma as an Early Diagnostic Tool in HCC

Effects of Probiotic on Inflammation and Microbiota in Patients With NASH

Effect of Probiotic Co-administration With Omega-3 Fatty Acids on NAFLD

Microbiome Translocation in Different Circulatory Compartments in Decompensated Cirrhosis

Portal Hypertension in Non-alcoholic Fatty Liver Disease: Association With Cardiovascular Risk and Identification of Non-invasive Biomarkers (THESIS)

NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal

Surrogate Markers of Portal Pressure

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Study Of Bacterial/Fungal Infections in Hospitalized Patients With Liver Cirrhosis in China